Maze Therapeutics to Participate in Four Upcoming Investor Conferences

Rhea-AI Summary

Maze Therapeutics (Nasdaq: MAZE) said company management will participate in four investor conferences in November–December 2025: a Guggenheim fireside chat on Nov 11, 2025 at 9:30 a.m. ET, a TD Cowen fireside chat on Nov 13, 2025 at 2:00 p.m. ET, a Jefferies presentation in London on Nov 20, 2025 at 12:00 p.m. GMT / 7:00 a.m. ET, and an Evercore presentation on Dec 3, 2025 at 10:25 a.m. ET.

Live webcasts will be available in the Investors section of the company website and will be archived for 60 days after each presentation.

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that company management will participate in four upcoming investor conferences:

• Guggenheim 2^nd Annual Healthcare Innovation Conference; fireside chat on Tuesday, November 11, 2025, at 9:30 a.m. ET
• TD Cowen Immunology & Inflammation Summit; fireside chat on Thursday, November 13, 2025, at 2:00 p.m. ET
• Jefferies Global Healthcare Conference in London; presentation on Thursday, November 20, 2025, at 12:00 p.m. GMT / 7:00 a.m. ET
• 8^th Annual Evercore Healthcare Conference; presentation on Wednesday, December 3, 2025, at 10:25 a.m. ET
  
  

Live webcasts of the events will be available in the Investors section of the Maze Therapeutics website at www.mazetx.com and archived for 60 days following the presentations.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel small molecule precision medicines for patients with kidney and metabolic diseases, including obesity. Guided by its Compass™ platform, Maze pursues genetically validated targets by integrating variant discovery and functionalization to discover and advance small molecule programs with first- or best-in-class potential. Maze’s pipeline is led by MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD), and MZE782, a SLC6A19 inhibitor advancing to Phase 2 with the potential to treat both phenylketonuria (PKU) and chronic kidney disease (CKD). Maze is headquartered in South San Francisco. For more information, please visit mazetx.com, or follow the company on LinkedIn and X.

IR/Corporate Contact:
Amy Bachrodt, Maze Therapeutics
abachrodt@mazetx.com

Media Contact:
Amanda Lazaro, 1AB Media
Amanda@1ABMedia.com

FAQ

When will Maze Therapeutics present at the Jefferies Global Healthcare Conference (MAZE)?

Maze will present on Thursday, Nov 20, 2025 at 12:00 p.m. GMT / 7:00 a.m. ET.

How can investors watch Maze Therapeutics (MAZE) fireside chats on Nov 11 and Nov 13, 2025?

Live webcasts will be available in the company's Investors section and archived for 60 days.

What dates and times is Maze scheduled to appear at investor conferences in November–December 2025?

Maze appears on Nov 11 (Guggenheim), Nov 13 (TD Cowen), Nov 20 (Jefferies London), and Dec 3 (Evercore).

Where will Maze Therapeutics (MAZE) host archived webcasts after the presentations?

Archived webcasts will be hosted in the Investors section of www.mazetx.com for 60 days.

Will Maze Therapeutics (MAZE) do a fireside chat at the Guggenheim Healthcare Innovation Conference?

Yes, management will participate in a Guggenheim fireside chat on Tuesday, Nov 11, 2025 at 9:30 a.m. ET.

Is the Evercore Healthcare Conference presentation by Maze Therapeutics (MAZE) live or pre-recorded?

The announcement states a presentation on Dec 3, 2025 at 10:25 a.m. ET and that live webcasts will be available on the company's investor site.